Prediction and prevention of preterm birth

Obstetrics and Gynecology

Volumn 120, Issue 4, 2012, Pages 964-973

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYPROGESTERONE CAPROATE; PROGESTERONE;

ARTICLE; CERVICAL LENGTH MEASUREMENT; COST EFFECTIVENESS ANALYSIS; CURETTAGE; DRUG EFFICACY; DRUG SAFETY; ENVIRONMENTAL FACTOR; FETUS ECHOGRAPHY; GESTATIONAL AGE; HEALTH CARE ACCESS; HEALTH CARE QUALITY; HUMAN; INFECTION PREVENTION; MATERNAL CARE; MATERNAL NUTRITION; MATERNAL SMOKING; MULTIPLE PREGNANCY; PREGNANCY COMPLICATION; PREMATURE LABOR; PRIORITY JOURNAL; PYELONEPHRITIS; RISK FACTOR; TRANSVAGINAL ECHOGRAPHY; TWIN PREGNANCY; UTERINE CERVIX CERCLAGE; UTERINE CERVIX CONIZATION;

EID: 84866939386     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/AOG.0b013e3182723b1b     Document Type: Article

References (72)

1. Martin JA, Hamilton BE, Sutton PD, Ventura SJ, Mathews TJ, Osterman MJ. Births: final data for 2008. Natl Vital Stat Rep 2010;59:1-72. (Level II-3)
2. Goldenberg RL, Culhane JF, Iams JD, Romero R. Epidemiology and causes of preterm birth. Lancet 2008;371:75-84. (Level III)
3. Wood NS, Marlow N, Costeloe K, Gibson AT, Wilkinson AR. Neurologic and developmental disability after extremely preterm birth. EPICure Study Group. N Engl J Med 2000;343:378-84. (Level II-2)
4. Preterm singleton births-United States, 1989-1996. Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep 1999;48:185-9. (Level II-3)
5. Simhan NH, Iams JD, Romero R. Preterm birth. In: Gabbe SG, Niebyl JR, Simpson JL, Landon MB, Galan HL, Jauniaux ER, et al, editors. Obstetrics: normal and problem pregnancies. 6th ed. Philadelphia (PA): Elsevier Saunders; 2012. p. 628-56. (Level III)
6. Martin JA, Hamilton BE, Ventura SJ, Osterman MJ, Kirmeyer S, Mathews TJ, et al. Births: final data for 2009. Natl Vital Stat Rep 2011;60:1-71. (Level II-3)
7. Clark SL, Miller DD, Belfort MA, Dildy GA, Frye DK, Meyers JA. Neonatal and maternal outcomes associated with elective term delivery. Am J Obstet Gynecol 2009;200:156.e1-4. (Level II-3)
8. Fleischman AR, Oinuma M, Clark SL. Rethinking the def-inition of "term pregnancy." Obstet Gynecol 2010;116:136-9. (Level III)
9. Spong CY. Prediction and prevention of recurrent spontaneous preterm birth. Obstet Gynecol 2007;110:405-15. (Level III)
10. McManemy J, Cooke E, Amon E, Leet T. Recurrence risk for preterm delivery. Am J Obstet Gynecol 2007;196:576.e1-6; discussion 576.e6-7. (Level II-3)
11. Bakketeig LS, Hoffman HJ. Epidemiology of preterm birth: results from a longitudinal study of births in Norway. In: Elder MG, Hendricks CH, editors. Preterm labor. Boston (MA): Butterworths; 1981. p. 17-46. (Level III)
12. Menard MK, Newman RB, Keenan A, Ebeling M. Prog-nostic significance of prior preterm twin delivery on subsequent singleton pregnancy. Am J Obstet Gynecol 1996;174:1429-32. (Level II-3)
13. Facco FL, Nash K, Grobman WA. Are women who have had a preterm twin delivery at greater risk of preterm birth in a subsequent singleton pregnancy? Am J Obstet Gynecol 2007;197:253.e1-3. (Level II-3)
14. Mella MT, Berghella V. Prediction of preterm birth: cervical sonography. Semin Perinatol 2009;33:317-24. (Level III)
15. Iams JD, Goldenberg RL, Meis PJ, Mercer BM, Moawad A,Das A, et al. The length of the cervix and the risk of spontaneous premature delivery. National Institute of Child Health and Human Development Maternal Fetal Medicine Unit Network. N Engl J Med 1996;334:567-72. (Level II-3)
16. Hassan SS, Romero R, Vidyadhari D, Fusey S, Baxter JK, Khandelwal M, et al. Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double-blind, placebo-controlled trial. PREGNANT Trial. Ultrasound Obstet Gynecol 2011;38:18-31. (Level I)
17. Crane JM, Hutchens D. Transvaginal sonographic measurement of cervical length to predict preterm birth in asymptomatic women at increased risk: a systematic review. Ultrasound Obstet Gynecol 2008;31:579-87. (Meta-analysis)
18. Shih W, Rushford DD, Bourne H, Garrett C, McBain JC, Healy DL, et al. Factors affecting low birthweight after assisted reproduction technology: difference between transfer of fresh and cryopreserved embryos suggests an adverse effect of oocyte collection. Hum Reprod 2008;23:1644-53. (Level II-3)
19. Jakobsson M, Gissler M, Sainio S, Paavonen J, Tapper AM. Preterm delivery after surgical treatment for cervical intraepithelial neoplasia [published erratum appears in Obstet Gynecol 2008;112:945]. Obstet Gynecol 2007;109:309-13. (Level II-3)
20. Sadler L, Saftlas A, Wang W, Exeter M, Whittaker J, McCowan L. Treatment for cervical intraepithelial neoplasia and risk of preterm delivery. JAMA 2004;291:2100-6.(Level II-3)
21. Shah PS, Zao J. Induced termination of pregnancy and low birthweight and preterm birth: a systematic review and meta-analyses. Knowledge Synthesis Group of Determinants of Preterm/LBW Births. BJOG 2009;116:1425-42. (Meta-analysis)
22. Schieve LA, Handler A, Hershow R, Persky V, Davis F. Urinary tract infection during pregnancy: its association with maternal morbidity and perinatal outcome. Am J Public Health 1994;84:405-10. (Level II-3)
23. Klein LL, Gibbs RS. Infection and preterm birth. Obstet Gynecol Clin North Am 2005;32:397-410. (Level III)
24. Romero R, Oyarzun E, Mazor M, Sirtori M, Hobbins JC, Bracken M. Meta-analysis of the relationship between asymptomatic bacteriuria and preterm delivery/low birth weight. Obstet Gynecol 1989;73:576-82. (Meta-analysis)
25. Vazquez JC, Abalos E. Treatments for symptomatic urinary tract infections during pregnancy. Cochrane Database of Systematic Reviews 2011, Issue 1. Art. No.: CD002256. DOI: 10.1002/14651858.CD002256.pub2. (Meta-analysis)
26. Meis PJ, Goldenberg RL, Mercer B, Moawad A, Das A,McNellis D, et al. The preterm prediction study: significance of vaginal infections. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Am J Obstet Gynecol 1995;173:1231-5. (Level II-2)
27. Schnarr J, Smaill F. Asymptomatic bacteriuria and symptomatic urinary tract infections in pregnancy. Eur J Clin Invest 2008;38(suppl 2):50-7. (Level III)
28. Michalowicz BS, Hodges JS, DiAngelis AJ, Lupo VR, Novak MJ, Ferguson JE, et al. Treatment of periodontal disease and the risk of preterm birth. OPT Study. N Engl J Med 2006;355:1885-94. (Level I)
29. Offenbacher S, Beck JD, Jared HL, Mauriello SM, Mendoza LC, Couper DJ, et al. Effects of periodontal therapy on rate of preterm delivery: a randomized controlled trial. Maternal Oral Therapy to Reduce Obstetric Risk (MOTOR) Investigators. Obstet Gynecol 2009;114:551-9. (Level I)
30. Macones GA, Parry S, Nelson DB, Strauss JF, Ludmir J,Cohen AW, et al. Treatment of localized periodontal dis-ease in pregnancy does not reduce the occurrence of preterm birth: results from the Periodontal Infections and Prematurity Study (PIPS). Am J Obstet Gynecol 2010;202:147.e1-8. (Level I)
31. Newnham JP, Newnham IA, Ball CM, Wright M, Pennell CE, Swain J, et al. Treatment of periodontal disease during pregnancy: a randomized controlled trial. Obstet Gynecol 2009;114:1239-48. (Level I)
32. Hickey CA, Cliver SP, McNeal SF, Goldenberg RL. Low pregravid body mass index as a risk factor for preterm birth: variation by ethnic group. Obstet Gynecol 1997;89:206-12. (Level II-3)
33. Zhong Y, Cahill AG, Macones GA, Zhu F, Odibo AO.The association between prepregnancy maternal body mass index and preterm delivery. Am J Perinatol 2010;27:293-8. (Level II-3)
34. Lumley J, Chamberlain C, Dowswell T, Oliver S, Oakley L, Watson L. Interventions for promoting smoking cessation during pregnancy. Cochrane Database of Systematic Reviews 2009, Issue 3. Art. No.: CD001055. DOI: 10.1002/14651858.CD001055.pub3. (Meta-analysis)
35. Polakowski LL, Akinbami LJ, Mendola P. Prenatal smoking cessation and the risk of delivering preterm and small-for-gestational-age newborns. Obstet Gynecol 2009;114:318-25. (Level II-3)
36. Zhu BP. Effect of interpregnancy interval on birth out-comes: findings from three recent US studies. Int J Gynaecol Obstet 2005;89(suppl 1):S25-33. (Level III)
37. Sonek JD, Iams JD, Blumenfeld M, Johnson F, Landon M,Gabbe S. Measurement of cervical length in pregnancy: comparison between vaginal ultrasonography and digital examination. Obstet Gynecol 1990;76:172-5. (Level II-2)
38. Doyle NM, Monga M. Role of ultrasound in screening patients at risk for preterm delivery. Obstet Gynecol Clin North Am 2004;31:125-39. (Level III)
39. Leitich H, Brunbauer M, Kaider A, Egarter C, Husslein P. Cervical length and dilatation of the internal cervical os detected by vaginal ultrasonography as markers for pre term delivery: a systematic review. Am J Obstet Gynecol 1999;181:1465-72. (Meta-analysis)
40. Kusanovic JP, Espinoza J, Romero R, Goncalves LF, Nien JK, Soto E, et al. Clinical significance of the presence of amniotic fluid 'sludge' in asymptomatic patients at high risk for spontaneous preterm delivery. Ultrasound Obstet Gynecol 2007;30:706-14. (Level II-3)
41. Faye-Petersen OM. The placenta in preterm birth. J Clin Pathol 2008;61:1261-75. (Level III)
42. Owen J, Iams JD. What we have learned about cervical ultrasound. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Semin Perinatol 2003;27:194-203. (Level III)
43. Berghella V, Roman A, Daskalakis C, Ness A, Baxter JK. Gestational age at cervical length measurement and incidence of preterm birth. Obstet Gynecol 2007;110:311-7. (Level II-3)
44. Dyson DC, Danbe KH, Bamber JA, Crites YM, Field DR, Maier JA, et al. Monitoring women at risk for preterm labor. N Engl J Med 1998;338:15-9. (Level I)
45. Andrews WW, Sibai BM, Thom EA, Dudley D, Ernest JM, McNellis D, et al. Randomized clinical trial of metronidazole plus erythromycin to prevent spontaneous preterm delivery in fetal fibronectin-positive women. National Institute of Child Health & Human Development Maternal-Fetal Medicine Unit Network. Obstet Gynecol 2003;101:847-55. (Level I)
46. Carey JC, Klebanoff MA, Hauth JC, Hillier SL, Thom EA, Ernest JM, et al. Metronidazole to prevent preterm delivery in pregnant women with asymptomatic bacterial vaginosis. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med 2000;342:534-40. (Level I)
47. Olsen SF, Secher NJ, Tabor A, Weber T, Walker JJ, Gluud C. Randomised clinical trials of fish oil supplementation in high risk pregnancies. Fish Oil Trials In Pregnancy (FOTIP) Team. BJOG 2000;107:382-95. (Level I)
48. Harper M, Thom E, Klebanoff MA, Thorp J Jr, Sorokin Y,Varner MW, et al. Omega-3 fatty acid supplementation to prevent recurrent preterm birth: a randomized controlled trial. Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Obstet Gynecol 2010;115:234-42. (Level I)
49. Rumbold AR, Crowther CA, Haslam RR, Dekker GA, Robinson JS. Vitamins C and E and the risks of preeclampsia and perinatal complications. ACTS Study Group. N Engl J Med 2006;354:1796-806. (Level I)
50. Poston L, Briley AL, Seed PT, Kelly FJ, Shennan AH. Vitamin C and vitamin E in pregnant women at risk for pre-eclampsia (VIP trial): randomised placebo-controlled trial. Vitamins in Pre-eclampsia (VIP) Trial Consortium. Lancet 2006;367:1145-54. (Level I)
51. Levine RJ, Hauth JC, Curet LB, Sibai BM, Catalano PM, Morris CD, et al. Trial of calcium to prevent preeclampsia. N Engl J Med 1997;337:69-76. (Level I)
52. Hofmeyr GJ, Lawrie TA, Atallah AN, Duley L. Calcium supplementation during pregnancy for preventing hyper- tensive disorders and related problems. Cochrane Data-base of Systematic Reviews 2010, Issue 8. Art. No.: CD001059. DOI: 10.1002/14651858.CD001059.pub3. (Meta-analysis)
53. Kramer MS, Kakuma R. Energy and protein intake in pregnancy. Cochrane Database of Systematic Reviews 2010, Issue 3. Art. No.: CD000032. DOI: 10.1002/14651858.CD000032. (Meta-analysis)
54. Edlow AG, Srinivas SK, Elovitz MA. Second-trimester loss and subsequent pregnancy outcomes: What is the real risk? Am J Obstet Gynecol 2007;197:581.e1-6. (Level II-2)
55. Meis PJ, Klebanoff M, Thom E, Dombrowski MP, Sibai B, Moawad AH, et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network [published erratum appears in N Engl J Med 2003;349:1299]. N Engl J Med 2003;348:2379-85. (Level I)
56. Use of progesterone to reduce preterm birth. ACOG Committee Opinion No. 419. American College of Obste-tricians and Gynecologists. Obstet Gynecol 2008;112:963-5. (Level III)
57. Tita AT, Rouse DJ. Progesterone for preterm birth prevention: an evolving intervention. Am J Obstet Gynecol 2009;200:219-24. (Level III)
58. Owen J, Hankins G, Iams JD, Berghella V, Sheffield JS, Perez-Delboy A, et al. Multicenter randomized trial of cerclage for preterm birth prevention in high-risk women with shortened midtrimester cervical length. Am J Obstet Gynecol 2009;201:375.e1-8. (Level I)
59. Berghella V, Odibo AO, To MS, Rust OA, Althuisius SM. Cerclage for short cervix on ultrasonography: meta-analysis of trials using individual patient-level data. Obstet Gynecol 2005;106:181-9. (Meta-analysis)
60. Berghella V, Rafael TJ, Szychowski JM, Rust OA, Owen J. Cerclage for short cervix on ultrasonography in women with singleton gestations and previous preterm birth: a meta-analysis. Obstet Gynecol 2011;117:663-71. (Meta-analysis)
61. Berghella V, Figueroa D, Szychowski JM, Owen J, Hankins GD, Iams JD, et al. 17-alpha-hydroxyprogesterone caproate for the prevention of preterm birth in women with prior preterm birth and a short cervical length. Vaginal Ultrasound Trial Consortium. Am J Obstet Gynecol 2010;202:351.e1-6. (Level II-3)
62. Fonseca EB, Celik E, Parra M, Singh M, Nicolaides KH. Progesterone and the risk of preterm birth among women with a short cervix. Fetal Medicine Foundation Second Trimester Screening Group. N Engl J Med 2007;357:462-9. (Level I)
63. Cahill AG, Odibo AO, Caughey AB, Stamilio DM, Hassan SS, Macones GA, et al. Universal cervical length screening and treatment with vaginal progesterone to prevent preterm birth: a decision and economic analysis. Am J Obstet Gynecol 2010;202:548.e1-8. (Cost-benefit analysis)
64. Werner EF, Han CS, Pettker CM, Buhimschi CS, Copel JA, Funai EF, et al. Universal cervical-length screening to prevent preterm birth: a cost-effectiveness analysis. Ultra-sound Obstet Gynecol 2011;38:32-7. (Cost-effectiveness analysis)
65. To MS, Alfirevic Z, Heath VC, Cicero S, Cacho AM, Williamson PR, et al. Cervical cerclage for prevention of preterm delivery in women with short cervix: randomised controlled trial. Fetal Medicine Foundation Second Trimester Screening Group. Lancet 2004;363:1849-53. (Level I)
66. Goya M, Pratcorona L, Merced C, Rodo C, Valle L, Romero A, et al. Cervical pessary in pregnant women with a short cervix (PECEP): an open-label randomised controlled trial. Pesario Cervical para Evitar Prematuridad (PECEP) Trial Group. Lancet 2012;379:1800-6. (Level I)
67. Durnwald CP, Momirova V, Rouse DJ, Caritis SN, Peaceman AM, Sciscione A, et al. Second trimester cervical length and risk of preterm birth in women with twin gestations treated with 17-alpha hydroxyprogesterone caproate. Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. J Matern Fetal Neonatal Med 2010;23:1360-4. (Level II-3)
68. Rouse DJ, Caritis SN, Peaceman AM, Sciscione A, Thom EA, Spong CY, et al. A trial of 17 alpha-hydroxyprogesterone caproate to prevent prematurity in twins. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. N Engl J Med 2007;357:454-61. (Level I)
69. Norman JE, Mackenzie F, Owen P, Mactier H, Hanretty K,Cooper S, et al. Progesterone for the prevention of pre term birth in twin pregnancy (STOPPIT): a randomised, double-blind, placebo-controlled study and meta-analysis. Lancet 2009;373:2034-40. (Level I)
70. Combs CA, Garite T, Maurel K, Das A, Porto M. 17-hydroxyprogesterone caproate for twin pregnancy: a double-blind, randomized clinical trial. Obstetrix Collaborative Research Network. Am J Obstet Gynecol 2011;204:221.e1-8. (Level I)
71. Caritis SN, Rouse DJ, Peaceman AM, Sciscione A, Momirova V, Spong CY, et al. Prevention of preterm birth in triplets using 17 alpha-hydroxyprogesterone caproate: a randomized controlled trial. Eunice Kennedy Shriver National Institute of Child Health and Human Develop-ment (NICHD), Maternal-Fetal Medicine Units Network (MFMU). Obstet Gynecol 2009;113:285-92.(Level I)
72. Combs CA, Garite T, Maurel K, Das A, Porto M. Failure of 17-hydroxyprogesterone to reduce neonatal morbidity or prolong triplet pregnancy: a double-blind, randomized clinical trial. Obstetrix Collaborative Research Network [published erratum appears in Am J Obstet Gynecol 2011;204:166]. Am J Obstet Gynecol 2010;203:248.e1-9. (Level I)